NCT05822362View on ClinicalTrials.gov

CBD for Individuals at Risk for Alzheimer's Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

January 19, 2024

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2029

Conditions
Mild Cognitive Impairment
Interventions
DRUG

Cannabidiol

The current study will directly test the hypothesis that a moderate dose of CBD improves markers of Alzheimer's progression, cognitive function, sleep, pain, anxiety, oxidative stress, and inflammation.

OTHER

Placebo

Placebo arm.

Trial Locations (1)

80045

RECRUITING

University of Colorado - Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER